CA2285556A1 - Calcilytic compounds - Google Patents

Calcilytic compounds Download PDF

Info

Publication number
CA2285556A1
CA2285556A1 CA002285556A CA2285556A CA2285556A1 CA 2285556 A1 CA2285556 A1 CA 2285556A1 CA 002285556 A CA002285556 A CA 002285556A CA 2285556 A CA2285556 A CA 2285556A CA 2285556 A1 CA2285556 A1 CA 2285556A1
Authority
CA
Canada
Prior art keywords
compounds
disease
compound
bone
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002285556A
Other languages
English (en)
French (fr)
Inventor
Pradip Kumar Bhatnagar
Amparo Maria Lago
Thomas T. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2285556A1 publication Critical patent/CA2285556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
CA002285556A 1997-04-04 1998-04-03 Calcilytic compounds Abandoned CA2285556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4306297P 1997-04-04 1997-04-04
US60/043,062 1997-04-04
PCT/US1998/006618 WO1998044925A1 (en) 1997-04-04 1998-04-03 Calcilytic compounds

Publications (1)

Publication Number Publication Date
CA2285556A1 true CA2285556A1 (en) 1998-10-15

Family

ID=21925269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002285556A Abandoned CA2285556A1 (en) 1997-04-04 1998-04-03 Calcilytic compounds

Country Status (4)

Country Link
EP (1) EP0998283A1 (ja)
JP (1) JP2001519813A (ja)
CA (1) CA2285556A1 (ja)
WO (1) WO1998044925A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351075A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd. Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
EP1355645A4 (en) * 2000-12-29 2005-02-23 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER IIIC INDICATIONS
DK1243581T3 (da) * 2001-03-21 2005-10-31 Torrent Pharmaceuticals Ltd Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
WO2007132179A2 (en) * 2006-05-15 2007-11-22 University Of Bath Therapeutics comprising pyridinium derivatives
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze

Also Published As

Publication number Publication date
JP2001519813A (ja) 2001-10-23
EP0998283A1 (en) 2000-05-10
WO1998044925A1 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
EP1070048B1 (en) Calcilytic compounds
US6335338B1 (en) Calcilytic compounds
US6417215B1 (en) Calcilytic compounds
CA2285556A1 (en) Calcilytic compounds
US20080234370A1 (en) Calcilytic Compounds
JP2007522148A (ja) カルシウム受容体アンタゴニスト化合物
US6291459B1 (en) Calcilytic compounds
US6864267B2 (en) Calcilytic compounds
EP1368318B1 (en) Calcilytic compounds
US20040009980A1 (en) Calcilytic compounds
EP1254106B1 (en) Calcilytic compounds
AU2001276923A1 (en) Calcilytic compounds
EP1664013B1 (en) Calcilytic compounds
US20040014723A1 (en) Calcilytic compounds
WO2005030746A1 (en) Calcilytic compounds
WO2006042007A2 (en) Chromenone compounds as calcilytics
US20020052509A1 (en) Calcilytic compounds and method of use

Legal Events

Date Code Title Description
FZDE Dead